On July 29, MIT Provost Martin A. Schmidt and Associate Provost Krystyn Van Vliet attended a groundbreaking ceremony to celebrate the construction of Landmark Bio, a new 40,000-square foot biopharma manufacturing facility at The Arsenal on the Charles in Watertown, Massachusetts. Jongyoon Han, MIT professor of electrical engineering and biological engineering, and Richard D. Braatz, the Edwin R. Gilliland Professor, faculty research officer, and professor of chemical engineering at MIT also attended the event.
Landmark Bio emerged from a public-private partnership formed in 2019 among MIT and four founding members: Harvard University, FUJIFILM Diosynth Biotechnologies, Cytiva, and Alexandria Real Estate Equities.
The facility — which will house manufacturing and development spaces under the same roof — is open to MIT faculty and their research groups conducting research to advance cell-based and RNA-based therapies for challenging diseases such as cancer, as well as for regenerative medicine. Landmark Bio’s mission is to advance and remove barriers to manufacturing technologies while serving as a forum for workforce development available to workers in Massachusetts and beyond.